Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Merit Medical Systems Q3 adjusted profit beats estimates on strong product demand; raises 2026 outlook

By Reuters News


Overview

  • U.S. medical device maker's Q3 revenue rose 8.4% yr/yr, with organic constant-currency revenue up 8.9%

  • Adjusted EPS for Q3 beat analyst expectations

  • Adjusted net income for Q3 beat analyst expectations


Outlook

  • Merit expects 2026 revenue between $1.635 bln and $1.642 bln

  • Company forecasts 2026 non-GAAP EPS of $4.33 to $4.37

  • Company expects 2026 constant-currency revenue growth of 7.0%-7.5%


Result Drivers

  • ORGANIC GROWTH - Co attributed results to 9% organic constant currency revenue growth, excluding impact of divestiture, per CEO Martha G. Aronson

  • PRODUCT DEMAND - Co said better-than-expected demand across Foundational and Therapeutic platforms drove revenue growth

  • THERAPEUTIC PLATFORM - Revenue rose 14% yr/yr, led by 33% growth in Endoscopy, 32% in OEM and 16% in Oncology


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Adjusted EPS

Beat

$1.12

$1.04 (11 Analysts)

Q3 EPS

$0.70

Q3 Adjusted Net Income

Beat

$67.40 mln

$62.79 mln (10 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Merit Medical Systems Inc is $100.00, about 8.4% above its October 28 closing price of $92.21

  • The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 16 three months ago


Reuters Recommended Reads

  • Oct 28 - Boston Scientific Q3 revenue beats estimates despite cybersecurity disruption

  • Oct 29 - West Pharmaceutical tops Q3 net sales, profit expectations, raises FY guidance

  • Oct 28 - Boston Scientific warns of tough 2027 on China pricing, heart-device weakness


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.